Találati lista | Tudóstér

001-es BibID:	BIBFORM007130
Első szerző:	Szekanecz Zoltán (reumatológus, belgyógyász, immunológus)
Cím:	Anti-citrullinated protein antibodies in rheumatoid arthritis : as good as it gets? / Szekanecz, Z., Soos, L., Szabo, Z., Fekete, A., Kapitany, A., Vegvari, A., Sipka, S., Szucs, G., Szanto, S., Lakos, G.
Dátum:	2008
ISSN:	1080-0549 (Print)
Megjegyzések:	Anti-citrullinated protein antibodies (ACPAs) have recently emerged as sensitive and specific serological markers of rheumatoid arthritis (RA), providing superior alternative of the rheumatoid factor (RF) test in the laboratory diagnostics of RA. The first members of this autoantibody family were anti-perinuclear factor (APF) and anti-keratin antibodies (AKA). It became evident that both APF and AKA recognize citrullinated epitopes of filaggrin. Citrullination is a post-translational modification of arginine by deimination, physiologically occurring during apoptosis, inflammation or keratinization. The presence of several citrullinated proteins has been demonstrated in the RA synovium. The identification of citrullinated epitopes as targets for anti-filaggrin antibodies led to the development of the first and later second generation anti-cyclic citrullinated peptide (anti-CCP) antibody assays. The widely used anti-CCP2 assays have high diagnostic sensitivity and specificity, and they also show important predictive and prognostic value in RA. The anti-Sa antibody has been identified a decade ago; however, recent studies confirmed that anti-Sa is directed against citrullinated vimentin, hence it is a new member of the family of ACPAs. The newly developed anti-mutated citrullinated vimentin (anti-MCV) assay has similar diagnostic performance than the anti-CCP2 ELISA; however, the diagnostic spectrum of the anti-MCV test is somewhat different from that of anti-CCP2. It's especially useful in the diagnosis of RA in RF and anti-CCP2 seronegative patients. The combined application of anti-CCP2 and anti-MCV assays can improve the laboratory diagnostics of RA. The family of ACPAs is expected to expand; there is an increasing need for developing new diagnostic strategies after careful evaluation of the characteristics of the available assays.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Arthritis, Rheumatoid/diagnosis/immunology Autoantibodies/blood Humans Peptides, Cyclic/immunology Vimentin/immunology
Megjelenés:	Clinical Reviews in Allergy and Immunology. - 34 : 1 (2008), p. 26-31. -
További szerzők:	Soós Lilla Szabó Zoltán (1970-) (belgyógyász, reumatológus) Fekete Andrea (immunológus) Kapitány Anikó (1979-) (molekuláris biológus) Végvári Anikó (belgyógyász, III. sz. Belgyógyászati Klinika) Sipka Sándor (1945-) (laboratóriumi szakorvos) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szántó Sándor (1968-) (belgyógyász, reumatológus) Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus)
Internet cím:	elektronikus változat DOI elektronikus változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM001205
035-os BibID:	PMID:17916982
Első szerző:	Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:	Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies : a 5-year follow-up / Tünde Tarr, Gabriella Lakos, Harjit Pal Bhattoa, Pál Soltész, Yehuda Shoenfeld, Gyula Szegedi, Emese Kiss
Dátum:	2007
Megjegyzések:	Objective: To analyze the association of antiphospholipid antibodies (aPL) with the development of clinical thrombotic manifestations and to characterize the efficacy of anti-thrombotic therapies used. Methods: 272 systemic lupus erythematosus (SLE) patients participated in the study. Patient files and a cumulative database were used to collect patients' medical histories. Anti-cardiolipin (aCL), anti-beta2-glycoprotein I (a??2GPI) antibodies, and lupus anticoagulant (LAC) were measured according to international recommendations. New thrombotic events were registered during follow-up. Results: The patients were prospectively studied for 5 years, of whom 107 were aPL negative (aPL- group). Criteria for antiphospholipid syndrome (APS) were fulfilled by 84 of 165 aPL-positive patients (APS+ group) indicating that SLE patients with aPL have around 50% risk to develop thrombotic complications. The aPL+ group (n?ë♯n81) consisted of aPL+ but APS- patients. LAC was the most common aPL (n?ë♯n27, 32.1%) in patients with APS. The cumulative presence of aPL further increased the prevalence of thrombotic events. During the follow-up period, aPL developed in 8 of 107 patients (7.5%) from the aPL- group, of whom 3 (2.8%) presented with thrombotic complications. Other types of aPL developed in 7 of 165 (4.2%) aPL+ patients within 5 years. New thrombotic events occurred in 3.7% of aPL+ (n?ë♯n3) and 8.3% (n?ë♯n7) of the APS group. During follow-up, 52 of 81 aPL+ patients received primary prophylaxis, and 1 (1.9%) had transient ischemic attack (TIA). In the non-treatment group, 2 (6.9%) had stroke. Seventy-nine of 84 of the APS patients received secondary prophylaxis, and myocardial infarction occurred in 2 patients (on cumarine therapy maintaining an international normalized ratio around 2.5-3.0), and 5 suffered a stroke/TIA (1 on aspirin and 4 on aspirin+cumarine). Conclusion: The findings emphasize the importance of determining both aCL and a??2GPI antibodies and LAC in SLE patients and the need for adequate anticoagulant therapy. ?? Humana Press Inc. 2007.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban SLE antiphospholipid antibodies thrombotic manifestation APS Follow-up LAC Primary prophylaxis acetylsalicylic acid antithrombocytic agent beta2 glycoprotein 1 antibody cardiolipin antibody coumarin lupus anticoagulant phospholipid antibody adult antiphospholipid syndrome article cerebrovascular accident cohort analysis controlled study data base deep vein thrombosis disease association disease course drug efficacy female follow uphigh risk population history of medicine human international normalized ratio lung embolism major clinical study male medical record prevalence prophylaxis prospective study stroke systemic lupus erythematosus thrombosis transient ischemic attack Adult Antibodies, Antiphospholipid Antibody Specificity Anticoagulants Antiphospholipid Syndrome Aspirin Cohort Studies Female Follow-Up Studies Humans Lupus Erythematosus, Systemic Male Middle Aged Thrombosis Time Factors egyetemen (Magyarországon) készült közlemény
Megjelenés:	Clinical Review of Allergy Immunology 32 : 2 (2007), p. 131-137. -
További szerzők:	Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Soltész Pál (1961-) (belgyógyász, kardiológus) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI Szerző által megadott URL
Borító:
Saját polcon: